Sangamo Therapeutics (SGMO) News Today $1.12 -0.01 (-0.45%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendationFebruary 19 at 2:20 AM | marketbeat.comTD Cowen Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)February 7, 2025 | markets.businessinsider.comSangamo announces updated data from STAAR studyFebruary 6, 2025 | markets.businessinsider.comSangamo reports positive Fabry disease gene therapy resultsFebruary 6, 2025 | msn.comSangamo reports updated data for gene therapy candidate ST-920February 6, 2025 | msn.comSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileFebruary 6, 2025 | businesswire.comGolden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 2,592.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 325,684 shares of the biopharmaceutical company's stock aftFebruary 4, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for SGMO FY2024 Earnings?Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright cut their FY2024 earnings per share estimates for Sangamo Therapeutics in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of ($0.49)January 30, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOJanuary 28, 2025 | prnewswire.comSangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday.January 28, 2025 | marketbeat.comSangamo Biosciences Receives ‘Buy’ Rating from Patrick Trucchio Amid Anticipated Collaborations and Gene Therapy AdvancesJanuary 27, 2025 | markets.businessinsider.comExpert Outlook: Sangamo Therapeutics Through The Eyes Of 11 AnalystsJanuary 27, 2025 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday.January 27, 2025 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four havJanuary 25, 2025 | marketbeat.comSangamo price target lowered to $5 from $7 at TruistJanuary 24, 2025 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)January 23, 2025 | markets.businessinsider.comTruist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00Truist Financial cut their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday.January 23, 2025 | marketbeat.comSangamo Biosciences Holds Steady Amid Partnership Prospects and Program UncertaintiesJanuary 18, 2025 | markets.businessinsider.comSangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025January 7, 2025 | msn.comPFE Returns Rights to Hemophilia A Candidate to Partner SGMOJanuary 3, 2025 | finance.yahoo.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...January 3, 2025 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOJanuary 2, 2025 | prnewswire.comSangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationJanuary 2, 2025 | businesswire.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmJanuary 2, 2025 | businesswire.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzJanuary 2, 2025 | businesswire.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday.January 2, 2025 | marketbeat.comSangamo Biosciences: Overcoming Setbacks with Strategic Partnerships and Fabry Program PotentialJanuary 1, 2025 | markets.businessinsider.com9 Analysts Have This To Say About Sangamo TherapeuticsJanuary 1, 2025 | benzinga.comSangamo Therapeutics: Left At The Alter (Rating Downgrade)January 1, 2025 | seekingalpha.comSangamo Therapeutics (NASDAQ:SGMO) Given New $3.00 Price Target at Jefferies Financial GroupJefferies Financial Group reduced their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday.December 31, 2024 | marketbeat.comCrude Oil Rises 1%; Sangamo Therapeutics Shares PlummetDecember 31, 2024 | benzinga.comSangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug PactDecember 31, 2024 | investopedia.comSangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy PactDecember 31, 2024 | benzinga.comSangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionDecember 31, 2024 | benzinga.comSangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s CautiousDecember 31, 2024 | msn.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by AnalystsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the four brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and three have given a buy rating to tDecember 31, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Price Target Cut to $2.00 by Analysts at Wells Fargo & CompanyWells Fargo & Company dropped their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a report on Tuesday.December 31, 2024 | marketbeat.comBarclays Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)December 31, 2024 | markets.businessinsider.comSangamo Therapeutics Shares Drop 55% After Termination of Pfizer DealDecember 30, 2024 | marketwatch.comSangamo down 31% at $1.61 after Pfizer decision to terminate collaborationDecember 30, 2024 | markets.businessinsider.comSangamo To Regain Rights To Hemophilia Therapy After Pfizer's Decides To Terminate CollaborationDecember 30, 2024 | markets.businessinsider.comPfizer Ends Sangamo Partnership for Hemophilia TherapyDecember 30, 2024 | marketwatch.comWhy Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comSangamo to reclaim hemophilia A therapy rights post Pfizer terminationDecember 30, 2024 | reuters.comSangamo Therapeutics (NASDAQ:SGMO) Shares Down 6.3% - Here's WhySangamo Therapeutics (NASDAQ:SGMO) Shares Down 6.3% - Should You Sell?December 30, 2024 | marketbeat.comBiotech Year In Review: SGMO Up 700%, CORT Surges 400%, AUPH & JANX DoubleDecember 29, 2024 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.comStockNews.com cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday.December 24, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Shares Gap Down - Here's WhySangamo Therapeutics (NASDAQ:SGMO) Shares Gap Down - Time to Sell?December 23, 2024 | marketbeat.comSangamo Biosciences: Strategic Neurology Advancements and Financial Growth Potential with Astellas PartnershipDecember 20, 2024 | markets.businessinsider.comSangamo: Pipeline Expansion Via Partnership And Internal ST-503 DevelopmentDecember 19, 2024 | seekingalpha.com Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼1.020.60▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼13▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EBS News RIGL News CDXS News XOMA News IRWD News VSTM News VNDA News LXRX News ACHV News AGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMO Stock Alerts